Taxanes have become front-line therapy for a variety of metastatic cancers, but resistance can develop, a frequent problem in breast, ovarian, prostate and other cancers. Now, researchers report a protein involved in taxane resistance that could potentially be targeted with drugs, making a cancer more susceptible to chemotherapy, and could potentially also serve as a biomarker in monitoring response to treatment.